CSII · Cardiovascular Systems Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | $236.22M | $258.97M | $236.54M | $204.91M | - | - |
| Cost of Revenue | $63.44M | $61.13M | $48.76M | $39.44M | - | - |
| Gross Profit | $172.78M | $197.84M | $187.79M | $200.34M | $177.56M | $165.47M |
| R&D | $36.72M | $41.06M | $43.35M | $33.46M | $26.76M | $22.91M |
| SG&A | $170.53M | $167.50M | $169.97M | $167.70M | $148.57M | $144.10M |
| Total Operating Expenses | $208.59M | $209.78M | $214.56M | $201.16M | $175.32M | $167.01M |
| D&A | $3.69M | $3.10M | $2.94M | $3.15M | $3.73M | $3.92M |
| Operating Income | ($35.81M) | ($11.93M) | ($26.77M) | ($825.0K) | $2.23M | ($1.54M) |
| Interest Expense | $1.63M | $1.74M | $1.97M | $1.68M | $1.72M | $500.0K |
| Income Tax | $310.0K | $252.0K | $231.0K | $190.0K | $132.0K | $92.0K |
| Net Income | ($36.93M) | ($13.42M) | ($27.24M) | ($255.0K) | $1.71M | ($1.79M) |
| EPS - Basic | ($0.35) | - | ($0.79) | ($0.01) | ($1.72) | ($0.06) |
| EPS - Diluted | ($0.35) | - | ($0.79) | ($0.01) | ($1.72) | ($0.06) |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $66.42M | $71.07M | $185.46M | $74.24M | $116.26M | $107.91M |
| Accounts Receivable | $39.68M | $40.03M | $25.21M | $36.02M | $31.23M | $28.47M |
| Inventory | $34.57M | $32.31M | $27.71M | $18.06M | $16.61M | $16.90M |
| Accounts Payable | $14.38M | $14.06M | $11.54M | $11.19M | $10.44M | $10.74M |
| Current Assets | $241.85M | $284.67M | $287.69M | $180.07M | $167.61M | $159.06M |
| Total Assets | $322.68M | $352.57M | $339.52M | $218.58M | $203.35M | $193.94M |
| Current Liabilities | $39.95M | $54.65M | $44.51M | $42.34M | $37.46M | $40.97M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $73.20M | $81.61M | $70.73M | $70.63M | $68.88M | $75.55M |
| Stockholders' Equity | $249.48M | $270.96M | $268.79M | $147.94M | $134.47M | $118.39M |
| Retained Earnings | ($423.68M) | ($381.38M) | ($363.07M) | ($329.54M) | ($327.59M) | ($329.30M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($24.27M) | ($884.0K) | ($12.77M) | $10.21M | $9.67M | $19.59M |
| Investing Cash Flow | $22.16M | ($112.71M) | ($8.67M) | ($54.35M) | ($5.09M) | ($1.78M) |
| Financing Cash Flow | ($2.54M) | ($800.0K) | $132.66M | $2.12M | $3.77M | $29.46M |
| CapEx | $4.22M | $3.95M | $3.37M | $2.67M | $1.96M | $981.0K |
| Free Cash Flow | ($28.49M) | ($4.84M) | ($16.13M) | $7.54M | $7.72M | $18.61M |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 73.1% | 76.4% | 79.4% | 97.8% | - | - |
| Operating margin | -15.2% | -4.6% | -11.3% | -0.4% | - | - |
| EBITDA margin | -13.6% | -3.4% | -10.1% | 1.1% | - | - |
| Net margin | -15.6% | -5.2% | -11.5% | -0.1% | - | - |
| Free cash flow margin | -12.1% | -1.9% | -6.8% | 3.7% | - | - |
| FCF / Net income | 0.77 | 0.36 | 0.59 | -29.58 | 4.51 | -10.38 |
| R&D / Revenue | 15.5% | 15.9% | 18.3% | 16.3% | - | - |
| SG&A / Revenue | 72.2% | 64.7% | 71.9% | 81.8% | - | - |
| Effective tax rate | - | - | - | - | 7.2% | - |
| Return on assets | -11.4% | -3.8% | -8.0% | -0.1% | 0.8% | -0.9% |
| Return on equity | -14.8% | -5.0% | -10.1% | -0.2% | 1.3% | -1.5% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 6.05 | 5.21 | 6.46 | 4.25 | 4.47 | 3.88 |
| Quick ratio | 5.19 | 4.62 | 5.84 | 3.83 | 4.03 | 3.47 |
| Cash ratio | 1.66 | 1.30 | 4.17 | 1.75 | 3.10 | 2.63 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -21.9x | -6.9x | -13.6x | -0.5x | 1.3x | -3.1x |
| Equity multiplier | 1.29 | 1.30 | 1.26 | 1.48 | 1.51 | 1.64 |
| Liabilities / Assets | 0.23 | 0.23 | 0.21 | 0.32 | 0.34 | 0.39 |
| Efficiency | ||||||
| Asset turnover | 0.73 | 0.73 | 0.70 | 0.94 | - | - |
| Inventory turnover | 1.84 | 1.89 | 1.76 | 2.18 | - | - |
| Days sales outstanding | 61d | 56d | 39d | 64d | - | - |
| Days inventory outstanding | 199d | 193d | 207d | 167d | - | - |
| Days payable outstanding | 83d | 84d | 86d | 104d | - | - |
| Cash conversion cycle | 177d | 165d | 160d | 128d | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | -8.8% | 9.5% | 15.4% | - | - | - |
| Revenue CAGR (3y) | 4.9% | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | -12.7% | 5.4% | -6.3% | 12.8% | 7.3% | 15.9% |
| Operating income growth (YoY) | -200.1% | 55.4% | -3145.1% | - | - | 97.3% |
| Net income growth (YoY) | -175.2% | 50.7% | -10580.8% | - | - | 96.8% |
| EPS growth (YoY) | - | - | -7800.0% | 99.4% | -2766.7% | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -488.9% | 70.0% | - | -2.3% | -58.5% | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -7.9% | 0.8% | 81.7% | 10.0% | 13.6% | 17.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2022-06-30.
Product / service
$236.22M totalPeripheral$156.01M · 66.0%
Coronary$80.21M · 34.0%
Geographic
$236.22M totalUS$219.84M · 93.1%
International$16.38M · 6.9%
Stability scores
Altman Z′
FY 2022 · bankruptcy risk
1.15
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2022 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✗No share dilution
- ✗Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Cardiovascular Systems Inc against the 5 most active filers in the same SIC group.